Dianne C. Whitfield is CHRO at Tarsus Pharmaceuticals, Inc. (TARS). They have made 10 open-market trades across 1 company since 2022, most recently 2026-03-19.
CIK 0001839516
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 10 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| TARS | 35,028 | $2.4M |
Shares reported on the most recent Form 4, priced at the 2026-03-19 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| TARS | SELL | 2026-03-17 | 2026-03-19 | $68.36 | $839K | +5.1% | -1.2% | -6.4% |
| TARS | SELL | 2026-01-02 | 2026-01-06 | $80.67 | $1.3M | -11.4% | -22.8% | -12.5% |
| TARS | SELL · 10b5-1 | 2025-12-16 | 2025-12-18 | $80.10 | $1.2M | +5.5% | -8.6% | -12.1% |
| TARS | SELL | 2025-03-18 | 2025-03-20 | $47.88 | $643K | -0.8% | -1.6% | -16.7% |
| TARS | SELL | 2024-03-18 | 2024-03-19 | $30.60 | $264K | +13.2% | +3.7% | -8.9% |
| TARS | SELL | 2023-11-30 | 2023-12-01 | $16.31 | $273K | +16.1% | +26.2% | +139.3% |
| TARS | SELL | 2023-03-21 | 2023-03-23 | $12.55 | $13K | +3.7% | +21.4% | +52.5% |
| TARS | SELL | 2023-03-17 | 2023-03-21 | $12.94 | $8K | -2.3% | +12.6% | +48.2% |
| TARS | SELL | 2023-03-16 | 2023-03-17 | $13.43 | $4K | -0.9% | -2.4% | +44.7% |
| TARS | SELL | 2022-12-02 | 2022-12-06 | $16.90 | $20K | -9.1% | -11.4% | -9.1% |
| TARS | SELL | 2022-11-30 | 2022-12-01 | $16.62 | $39K | -9.3% | -13.8% | -8.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.